1239908-20-3

Basic information

• Product Name: Ixazomib citrate (USAN)
• Synonyms: Ixazomib citrate (USAN);2-[(1R)-1-[[2-[(2,5-Dichlorobenzoyl)amino]acetyl]amino]-3-methylbutyl]-5-oxo-1,3,2-dioxaborolane-4,4-diacetic acid;2,2'-(2-(1-(2-(2,5-dichlorobenzamido)acetamido)-3-methylbutyl)-5-oxo-1,3,2-dioxaborolane-4,4-diyl)diacetic acid;(R)-2,2'-(2-(1-(2-(2,5-dichlorobenzamido)acetamido)-3-methylbutyl)-5-oxo-1,3,2-dioxaborolane-4,4-diyl)diacetic acid
• CAS NO: 1239908-20-3
• Molecular Formula: C20H23BCl2N2O9
• Molecular Weight: 517.12
• Mol File: 1239908-20-3.mol
• Article Data: 11

Chemical Properties

• Appearance: /
• Density: 1.47±0.1 g/cm3(Predicted)
• PKA: 3.59±0.10(Predicted)
• CAS DataBase Reference: Ixazomib citrate (USAN)(CAS DataBase Reference)
• NIST Chemistry Reference: Ixazomib citrate (USAN)(1239908-20-3)
• EPA Substance Registry System: Ixazomib citrate (USAN)(1239908-20-3)

Safety Data

• Hazardous Substances Data: 1239908-20-3(Hazardous Substances Data)

Usage

Definition

ChEBI: A glycine derivative that is the amide obtained by formal condensation of the carboxy group of N-(2,5-dichlorobenzoyl)glycine with the amino group of 2,2'-{2-[(1R)-1-amino-3-methylbutyl]-5-oxo-1,3,2-dioxaborolane-4,4-diy }diacetic acid. A prodrug for ixazomib that is used in combination therapy for treatment of multiple myeloma.

Upstream product

• 1072833-77-2 Ixazomib 
• 77-92-9 citric acid 
• 50-79-3 2,5-dichlorobenzoic acid 
• 1310383-72-2 (aR,3aS,4S,6S,7aR)-hexahydro-3a,8,8-trimethyl-α-(2-methylpropyl)-4,6-methano-1,3,2-benzodioxaborole-2-methanamine 2,2,2-trifluoroacetate 
• 667403-46-5 2-[(2,5-dichlorobenzoyl)amino]acetic acid 
• 7732-18-5 water 
• 5949-29-1 citric acid monohydrate 
• 1201903-02-7 2,5-dichloro-N-[2-({(1R)-3-methyl-1-[(3aS,4S,6S,7aR)-3a,5,5-trimethylhexa-hydro-2H-4,6-methano-1,3,2-benzodioxaborol-2-yl]butyl}amino)-2-oxoethyl]benzamide 

Relevant articles and documents

PROCESS FOR THE PREPARATION OF IXAZOMIB CITRATE

The present disclosure provides a process for the preparation of ixazomib citrate. An efficient, industrially feasible process for the preparation of ixazomib citrate of Formula I, optionally which the process can occur in a single pot.

A PROCESS FOR THE PREPARATION OF IXAZOMIB CITRATE

The present invention relates to a process for the preparation of compound of formula (I), wherein, R1 and R2 are each independently hydroxy, alkoxy, aryloxy, or aralkoxy; or R1 and R2 together form a moiety derived from an alpha-hydroxy carboxylic acid compound or a beta-hydroxy carboxylic acid compound, wherein the atom attached to boron in each case is an oxygen atom; or R1 and R2 together form the boronate esters of boronic acid.

NOVEL CRYSTALLINE FORMS OF IXAZOMIB CITRATE AND ITS PROCESS FOR PREPARATION THEREOF

The present invention related to novel crystalline forms of Ixazomib citrate of formula-I and its process for preparation thereof. The chemical structure of said compound represented by the following formula-I. This invention also provides a process for the preparation of Ixazomib citrate of formula-I and also its solid dispersions.